Moogene Medi Co., Ltd. (XKON:322970)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,075.00
+50.00 (2.47%)
At close: Aug 1, 2025, 3:30 PM KST
2.47%
Market Cap20.86B
Revenue (ttm)12.95M
Net Income (ttm)-2.08B
Shares Out10.05M
EPS (ttm)-332.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,387
Average Volume813
Open2,030.00
Previous Close2,025.00
Day's Range1,932.00 - 2,080.00
52-Week Range1,410.00 - 3,090.00
Beta-0.04
RSI45.82
Earnings Daten/a

About Aspen Technology

Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology. The company’s product portfolio comprises MG-001, which is in Phase I clinical trials to treat colon cancer; MG-002 that is in preclinical stage for use in the treatment of pancreatic cancer; and MG-003, which is in preclinical stage for use in the treatment of diabetes mellitus. Its research stage products include MG-004 for treating hair loss and MG-005 for use in the treatment of Crohn's disease. The company was founded in 2016 and is ba... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 322970
Full Company Profile

Financial Performance

In 2019, Moogene Medi's revenue was 12.95 million, a decrease of -87.17% compared to the previous year's 100.95 million. Losses were -2.08 billion, 41.4% more than in 2018.

Financial Statements

News

There is no news available yet.